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Phase II trial of pemetrexed and gemcitabine as first-line 
chemotherapy for elderly and/or poor performance status patients 
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Background: The combination of Pemetrexed (PEM) and Gemcitabine 
(GEM) in the treatment of locally advanced or metastatic NSCLC has 
shown synergy in both preclinical and clinical studies with a favorable 
toxicity proﬁle compared to other doublets. Late-stage and symptomat-
ic diagnosis in elderly patients remains an increasingly common prob-
lem. This study was designed to evaluate the efﬁcacy of this doublet 
as ﬁrst-line therapy for advanced NSCLC in the most difﬁcult to treat 
patients, i.e. older patients and those with poor performance status. The 
goal of this novel doublet regimen is to preserve the activity of two-
drug combinations while minimizing toxicity in an ‘at-risk’ population.
Methods: Patients with age > 65 and ECOG 0-2 or age < 65 and 
ECOG of 2, with locally advanced or metastatic (measurable stage 
IIIB/IV) NSCLC by RECIST criteria were treated with biweekly cycles 
of PEM 500mg/m2 IV over 10 minutes, followed by GEM 1500 mg/m2 
IV over 30 minutes on Day 1. Cycles were repeated every 2 weeks with 
a maximum of 12 cycles for stable or responding patients. All patients 
received vitamin B12 1000 µg and folic acid 1000 mg 7 days prior to 
the initiation of treatment and continued through treatment.
Results: 45 patients were enrolled to this study. The median age is 72 
(range 46-88). Five patients had stage IIIB and 40 stage IV, median 
number of sites of disease is 2. 62% are male. Patient performance 
status was as follows: ECOG 0=5, ECOG 1=27, ECOG 2=13 patients. 
Overall, 22 pts experienced a Grade 3 or 4 AE. Seven patients had 
grade 3 or 4 neutropenia with 2 patients having febrile neutropenia. 
There were 2 patients with grade 3 or 4 anemia, and one with throm-
bocytopenia. 30 patients were evaluable for best overall response, with 
1 achieving CR (3%), 6 with PR (20%), 16 with SD (53%) and 7 with 
PD (23%). Overall, clinical beneﬁt (CR+PR+SD) was seen in 76% of 
patients. 
Conclusion: Pemetrexed and Gemcitabine in combination on a 
biweekly schedule has substantial activity with a favorable toxicity 
proﬁle for elderly patients with advanced NSCLC. Overall response 
rates and clinical beneﬁts are comparable to contemporary platinum 
containing doublet regimens.
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Biweekly paclitaxel as second-line treatment in advanced non-
small-cell-lung-cancer (NSCLC). A phase II study of the Lung 
Cancer Galician Group
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Background: Paclitaxel is an active drug for NSCLC. Our purpose 
was to evaluate the efﬁcacy and toxicity of biweekly administration of 
this drug in previously treated patients with advanced NSCLC.
Methods: Patients with stage IIIB and IV NSCLC, which progressed 
after or during ﬁrst-line chemotherapy, measurable disease, ECOG 
PS=0-1 and adequate organ function were included. Paclitaxel was 
administered at 150 mg /m2 iv, days 1 and 14, every 28 days, for a 
maximum of six cycles. Both, toxicity and efﬁcacy analyses, were 
performed on the intent-to-treat (ITT) population.
Results: Between September 2004 and November 2006, 45 patients 
(M/F, 42/3) were included, with median age 62 years (39-79). Tumor 
histology mainly included epidermoid (42.2%) and adenocarcinoma 
(35.6%). Tumor stage was IIIB (24.4%) and IV (75.6%). Median 
number of metastatic lesions was 1 (57.8%), located mainly in lymph 
nodes (44.4%), lung (33.3%), adrenal glands (20%) and bone (13.3%). 
Previous chemotherapy included platinum (80%), docetaxel (64.4%) 
and gemcitabine (57.8%). A total of 251 cycles (median 5, range 1-6) 
were administered. Median relative dose intensity was 96.2%. Toxicity: 
Grade III/IV hematologic toxicities per patient were neutropenia (2.3%) 
and anemia (2.3%). Grade III/IV non-hematologic toxicities were 
asthenia (2.3%), arthralgias/myalgias (2.3%) and peripheral neuropathy 
(2.3%). Efﬁcacy: Of 45 ITT patients. 9 achieved PR, 11 SD and 17 pro-
gressed, resulting in an ORR of 20% (95%CI: 8.3-31.7%). 7 patients 
could not be evaluated due to early withdrawal (4 tumor-related exitus, 
1 PS deterioration, 1 hypersensibility reaction and 1 loss of follow-up). 
With an average follow-up time of 286 days, median TTP and OS were 
174 days (95%CI: 137.6-210.4) and 289 days (95%CI: 140.5-437.4), 
respectively.
Conclusions: Biweekly paclitaxel is an active and very well tolerated 
regimen in previously treated patients with advanced NSCLC. 
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Background: Topotecan, a semi-synthetic camptothecin analogue 
with topoisomerase I interaction has shown to be an active agent in the 
treatment of advanced refractory lung cancer and ovarian cancer. In 
this report, experience with this drug is described when used as a single 
agent in patients with advanced NSCLC refractory to chemotherapy 
regimens containing at least platinum and taxanes.
Material and Methods: twenty-four patients (pts) with NSCLC refrac-
tory to previous chemotherapy and KI ≥60% were included in the study 
showing the following features: median age of 52 years (range 43-69) 
and karnofsky PS of 70 (50-80), 21 were male and 3 female. Fifteen 
(62 %) pts had adenocarcinoma, six (25%) squamous cell and three 
(13%) undifferentiated carcinoma. The median number of disease sites 
and prior regimens received were two in both cases. Topotecan was 
given at a dose of 1.25 mg/m2 I.V. daily for ﬁve days, repeated every 21 
days until progression disease, maximal response or intolerable toxicity 
occurred.
